The present invention relates to a pharmaceutical combination preparation comprising an omega-3 fatty acid and an HMG-CoA reductase inhibitor having improved bioavailability, and the pharmaceutical combination preparation according to the present invention is an omega-3 fatty acid and an HMG-CoA reduction inhibitor It can effectively control the total cholesterol level, triglyceride level and low-density lipoprotein level in the blood, including effective in treating hyperlipidemia, and improve the bioavailability by improving the dissolution rate of HMG-CoA reduction inhibitor in gastric and intestinal fluid conditions. It has the effect. In addition, by securing a high content uniformity of the HMG-CoA reduction inhibitor, there is an effect that can prevent overdose due to the variation in the content of the drug. Furthermore, by additionally forming an external sealing coating layer on the surface of the formulation to which the statin-based drug is applied, there is an effect that the patient's rejection due to the bitter taste of the statin-based drug can be reduced to improve medication compliance. In addition, by adding a gelatin and a specific plasticizer to form a film of a capsule containing omega-3 fatty acids, it does not cause a delay in the release of omega-3 fatty acids and exhibits a suitable strength in the coating process, which is advantageous for industrial production. .
展开▼
